NCT06461078View on ClinicalTrials.gov

Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 22, 2024

Primary Completion Date

September 25, 2024

Study Completion Date

April 28, 2025

Conditions
Drug Kinetics
Interventions
DRUG

Radotinib HCl

"1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~4. Storage conditions: Store in an airtight light proof container at room temperature."

Trial Locations (1)

Unknown

Severance Hospital, Seoul

All Listed Sponsors
lead

Il-Yang Pharm. Co., Ltd.

INDUSTRY

NCT06461078 - Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib | Biotech Hunter | Biotech Hunter